3rdPartyFeeds

Aphria Inc. Announces Receipt of EU GMP Certification for Subsidiary ASG Pharma Ltd. and Liquidation of Promissory Note

Following receipt of its first medical cannabis import license for analytical testing and research in 2018 and the subsequent ASG facility upgrade, the certification provides Aphria with the ability to ship finished dried flower and finished oil for medicinal and research use in permitted jurisdictions throughout the European Union. "We are pleased to receive EU GMP certification for ASG in Malta , our third facility to achieve this milestone, which really speaks to the Company's commitment to quality," said Irwin D. Simon , Chief Executive Officer. Read More...

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="LEAMINGTON, ON , May 6, 2020 /CNW/ -&nbsp;Aphria Inc. ("Aphria" or the "Company") (TSX: APHA&nbsp;and NYSE: APHA) today announced that its subsidiary, ASG Pharma Ltd. ("ASG"), has received its European Union Good Manufacturing Practices ("EU GMP") certification from the Malta Medicines Authority ("MMA") in respect of production of cannabis for medicinal and research purposes.” data-reactid=”12″>LEAMINGTON, ON , May 6, 2020 /CNW/ – Aphria Inc. (“Aphria” or the “Company“) (TSX: APHA and NYSE: APHA) today announced that its subsidiary, ASG Pharma Ltd. (“ASG“), has received its European Union Good Manufacturing Practices (“EU GMP“) certification from the Malta Medicines Authority (“MMA“) in respect of production of cannabis for medicinal and research purposes.

Aphria Inc. Logo (CNW Group/Aphria Inc.)

Following receipt of its first medical cannabis import license for analytical testing and research in 2018 and the subsequent ASG facility upgrade, the certification provides Aphria with the ability to ship finished dried flower and finished oil for medicinal and research use in permitted jurisdictions throughout the European Union.

“We are pleased to receive EU GMP certification for ASG in Malta , our third facility to achieve this milestone, which really speaks to the Company’s commitment to quality,” said Irwin D. Simon , Chief Executive Officer. “We remain excited about growth opportunities as this increases our ability to serve, and further strengthens Aphria’s leadership, in the European Union.”

ASG is a high-capacity EU GMP-certified lab that is well-positioned to become a cornerstone for testing and research and development of medical cannabis in Europe . In addition, ASG will provide additional capacity for importing, processing, packaging and distribution of the Company’s EU-GMP certified cannabis products in Europe .

The Company also announced the liquidation of its C$39 million Promissory Note from GA Opportunities Corp. for proceeds of approximately C$26 million .

We Have A Good Thing Growing

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="About Aphria Inc.
Aphria Inc. is a leading global cannabis company driven by an unrelenting commitment to our people, the planet, product quality and innovation. Headquartered in Leamington, Ontario – the greenhouse capital of Canada – Aphria Inc. has been setting the standard for the low-cost production of high-quality cannabis at scale, grown in the most natural conditions possible. Focusing on untapped opportunities and backed by the latest technologies, Aphria Inc. is committed to bringing breakthrough innovation to the global cannabis market. The Company’s portfolio of brands is grounded in expertly-researched consumer insights designed to meet the needs of every consumer segment. Rooted in our founders’ multi-generational expertise in commercial agriculture, Aphria Inc. drives sustainable long-term shareholder value through a diversified approach to innovation, strategic partnerships and global expansion.” data-reactid=”30″>About Aphria Inc.
Aphria Inc. is a leading global cannabis company driven by an unrelenting commitment to our people, the planet, product quality and innovation. Headquartered in Leamington, Ontario – the greenhouse capital of Canada – Aphria Inc. has been setting the standard for the low-cost production of high-quality cannabis at scale, grown in the most natural conditions possible. Focusing on untapped opportunities and backed by the latest technologies, Aphria Inc. is committed to bringing breakthrough innovation to the global cannabis market. The Company’s portfolio of brands is grounded in expertly-researched consumer insights designed to meet the needs of every consumer segment. Rooted in our founders’ multi-generational expertise in commercial agriculture, Aphria Inc. drives sustainable long-term shareholder value through a diversified approach to innovation, strategic partnerships and global expansion.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="For more information, visit: aphriainc.com” data-reactid=”31″>For more information, visit: aphriainc.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking information or forward-looking statements (together, “forward-looking statements”) under applicable securities laws and are expressly qualified by this cautionary statement. Any information or statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements, including, but not limited to, statements in this news release with regards to the expected impact of the EU GMP certification on the Company’s business and expectations related to the Company’s market position. The Company uses words such as “forecast”, “future”, “should”, “could”, “enable”, “potential”, “contemplate”, “believe”, “anticipate”, “estimate”, “plan”, “expect”, “intend”, “may”, “project”, “will”, “would” and the negative of these terms or similar expressions to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Various assumptions were used in drawing the conclusions contained in the forward-looking statements throughout this news release. Forward-looking statements reflect management’s current beliefs with respect to future events and are based on information currently available to management including based on reasonable assumptions, estimates, internal and external analysis and opinions of management considering its experience, perception of trends, current conditions and expected developments as well as other factors that management believes to be relevant as at the date such statements are made. Forward-looking statements involve significant known and unknown risks and uncertainties. Many factors could cause actual results, performance or achievement to be materially different from any future forward-looking statements. Factors that may cause such differences include, but are not limited to, risks associated with COVID-19 nationally and globally which could have a material adverse impact on Aphria’s business, operations and financial results, including disruptions in cultivation and processing, supply chains and sales channels, as well as a deterioration of general economic conditions including national and/or global recessions and the response of governments to the COVID-19 pandemic in respect of the operation of retail stores; general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving cannabis or otherwise affecting Aphria’s business or its consumers generally; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the cannabis industry in Canada generally; income tax and regulatory matters, including delays in the issuance of licenses; the sale and distribution of vapes; the ability of Aphria to meet its liquidity requirements to fund ongoing operations; the ability of Aphria to implement its business strategies; competition; crop failure; safety of derivative cannabis products; currency and interest rate fluctuations.

Readers are cautioned that the foregoing list is not exhaustive and should carefully review the various risks and uncertainties identified in the Company’s filings on SEDAR and EDGAR. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities laws.  Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="View original content to download multimedia:http://www.prnewswire.com/news-releases/aphria-inc-announces-receipt-of-eu-gmp-certification-for-subsidiary-asg-pharma-ltd-and-liquidation-of-promissory-note-301053496.html” data-reactid=”51″>View original content to download multimedia:http://www.prnewswire.com/news-releases/aphria-inc-announces-receipt-of-eu-gmp-certification-for-subsidiary-asg-pharma-ltd-and-liquidation-of-promissory-note-301053496.html

SOURCE Aphria Inc.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2020/06/c9450.html” data-reactid=”72″>View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2020/06/c9450.html

Read More

Add Comment

Click here to post a comment